New Analyst Coverage on Resverlogix
A new analyst report has been published covering the cost benefits of RVX-208 and discussing our single epigenetic target with effects on multiple synchronized biological pathways. Marcel Wijma, chief...
View Article
Image may be NSFW.
Clik here to view.
Clik here to view.
Dr. Norman Wong presents at EAS Congress, Glasgow, Scotland
Dr. Norman CW Wong, CSO of Resverlogix presented data on RVX-208 at the European Atherosclerosis Society (EAS) annual meeting in an oral abstract entitled: “RVX-208 a selective bromodomain...
View ArticleACC.15 Highlight, CVD & Epigenetics
The American College of Cardiology Annual Scientific Session and Expo is one of the most important cardiology conferences. Each year, interesting news is announced and scientific findings are presented...
View Article
More Pages to Explore .....
